Jan Kalinovsky
Bayer HealthCare Pharmaceuticals
7 Papers
12 Citations
Jan Kalinovsky is an academic researcher from Bayer HealthCare Pharmaceuticals. The author has contributed to research in topics: Prostate cancer & Interim analysis. The author has an hindex of 3, co-authored 7 publications.
Chat about Author
Papers
PD-025Real-world dosing of regorafenib in metastatic colorectal cancer (mCRC): Interim analysis from the prospective, observational CORRELATE study
Manuel O’Connor Juan,Leopold Öhler,Werner Scheithauer,Jean-Philippe Metges,Louis-Marie Dourthe,Willem de Groot Jan,Josef Thaler,Kun-Huei Yeh,J.-K. Lin,Alfredo Falcone,Cornelis J. A. Punt,Jan Kalinovsky,Sabine Fiala-Buskies,Andrés Cervantes,Lone Petersen,Michel Ducreux +15 more
9
Impact of tumor location on outcomes in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): An interim analysis from the prospective, observational CORRELATE study.
Michel Ducreux,Leopold Öhler,Werner Scheithauer,Jean-Philippe Metges,Louis-Marie Dourthe,Jan Willem B. de Groot,Josef Thaler,Kun-Huei Yeh,Jen-Kou Lin,Alfredo Falcone,Cornelis J. A. Punt,Jan Kalinovsky,Sabine Fiala-Buskies,Andrés Cervantes,J. O’Connor +14 more
TL;DR: This exploratory analysis evaluated outcomes by primary tumor location in patients with mCRC treated with REG in the CORRELATE study to characterize the safety and effectiveness of REG in unselected patients for whom the decision to treat with REG has been made by the treating physician according to the local health authority label.
5
807P First interim results of the radium-223 (Ra-223) REASSURE observational study: analysis of patient (Pt) characteristics and safety by use of abiraterone and/or enzalutamide (Abi/Enza).
Lauren C. Harshman,John P Logue,Cora N. Sternberg,S. Sundar,D. Schrijvers,Martin Schostak,John Sylvester,Saby George,Marcello Tucci,Constantine Mantz,P. Borrega,P Ziem,R Concepcion,Kurt Miller,Oliver Sartor,Jan Kalinovsky,Y. De Sanctis,Bertrand Tombal +17 more
4
Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Daniel J. George,Cora N. Sternberg,A. Oliver Sartor,Fred Saad,Bertrand F. Tombal,Kurt Miller,Jan Kalinovsky,XiaoLong Jiao,Krishna Tangirala,Celestia S. Higano +9 more
TL;DR: Clinical outcomes in pts with mCRPC who received concurrent or layered Ra-223 + Abi treatment and prior therapies, and clinical outcomes including skeletal-related events (SREs) and overall survival (OS) are evaluated.
4
First interim results of the Radium-223 (Ra-223) reassure observational study in metastatic castration-resistant prostate cancer (mCRPC): Safety and baseline (BL) characteristics of U.S. patients (Pts) by prior/concomitant treatment (Tx).
Lauren C. Harshman,A. Oliver Sartor,Tim Richardson,John Sylvester,Danny Y. Song,Constantine Mantz,Robert K. Brookland,Mark Perlmutter,Robert Given,Jan Kalinovsky,Svetlana Babajanyan,Yoriko De Sanctis,Celestia S. Higano +12 more
TL;DR: A descriptive analysis of safety and BL characteristics of US pts according to prior or concomitant abiraterone/enzalutamide (abi/enza) or prior docetaxel/cabazitaxel (chemo) using data from the first planned interim analysis found prior abi/enza and/or chemo pts had higher median BL PSA and were less likely to complete 5-6 doses.
2